Inicio / Oncología / Abstracts de oncología / Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab

Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab

0 / 5 (0 votos)
Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab

Oncology: International Journal of Cancer Research and Treatment

Published online: January 2018

DOI: https://doi.org/10.1159/000485562

Schwab K.S.a · Kristiansen G.b · Schild H.H.c · Held S.E.A.a · Heine A.a · Brossart P.a 

Background: Treatment options for patients with platinum-refractory, recurrent, metastatic head and neck squamous cell carcinoma (HNSCC) are limited, and prognosis is poor. Nivolumab (Opdivo) has been approved by the US Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic HNSCC who have disease progression on or after platinum-based therapy. 

SEGUIR LEYENDO

Comentarios

Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.